{
    "clinical_study": {
        "@rank": "163248", 
        "acronym": "STATIS", 
        "arm_group": [
            {
                "arm_group_label": "Xpert MTB/RIF\u00ae, Determine TB LAM, Chest X-ray", 
                "arm_group_type": "Experimental", 
                "description": "Arm1  Extensive TB screening:\nIn this arm, point-of-care tests for TB will be used at randomization (in all patients) and at each scheduled or unscheduled follow-up visit (in patients with signs or symptoms suggestive of TB and no clear alternative diagnosis); TB treatment will only be prescribed to patients with a diagnosis of TB"
            }, 
            {
                "arm_group_label": "Rifampin, isoniazid, pyrazinamide, ethambutol", 
                "arm_group_type": "Experimental", 
                "description": "Arm 2: Systematic Empiric treatment (Rifampicin,isoniazid, pyrazinamide, ethambutol) ART\nIn this arm, all patients will start a systematic 6-month TB treatment at randomization. TB screening tests will not systematically be used neither at randomization nor while patients are on TB treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "In countries with a high tuberculosis (TB) prevalence, TB and invasive bacterial infections\n      are leading causes of early death in patients who initiate antiretroviral therapy (ART) with\n      advanced immunodeficiency.\n\n      We hypothesize that a systematic 6-month empirical TB treatment initiated 2 weeks before the\n      introduction of ART in HIV-infected adults with severe immunosuppression (CD4<100/mm3) and\n      no overt evidence of TB will reduce the risk of death and invasive bacterial infections.\n      This strategy will be compared to one of extensive TB testing using point-of-care tests\n      (Xpert MTB/RIF\u00ae and urine lipoarabinomanan LAM) and chest X-ray to identify and treat only\n      patients with at least one positive test suggestive of TB."
        }, 
        "brief_title": "Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV-1 Infection", 
        "condition_browse": {
            "mesh_term": [
                "Tuberculosis", 
                "HIV Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Settings: Cambodia, C\u00f4te d'Ivoire, Uganda, Vietnam. Design: Multicentre, two-arm, unblinded\n      randomized controlled superiority trial.\n\n      Objective: To compare the 24-week risk of death and occurrence of invasive bacterial\n      infection between two experimental strategies in HIV-1 infected adults who start ART with a\n      CD4 count <100/mm3: (i) continuous extensive TB screening during follow-up each time the\n      patient present with symptoms, versus (ii) systematic empirical TB treatment started 2 weeks\n      before ART initiation.\n\n      Trial strategies:\n\n      At inclusion, participants will be randomized 1:1 in two strategies of TB testing and\n      treatment: extensive TB screening, or systematic empirical TB treatment.\n\n      Extensive TB screening (arm 1): In this arm:\n\n        -  TB screening point-of-care tests (Xpert MTB/RIF\u00ae, urine LAM) and chest X-ray will be\n           used extensively at randomisation (in all patients) and during follow-up (in patients\n           with signs or symptoms suggestive of TB);\n\n        -  Only patients who meet standardized criteria for TB at inclusion or during follow-up\n           will receive a standard TB treatment (2ERHZ/4RH);\n\n        -  ART (tenofovir(TDF)-lamivudine (3TC)/emtricitabine(FTC) or zidovudine (AZT)-lamivudine+\n           efavirenz) will be started immediately after randomization in patients not put on TB\n           treatment, and 2 weeks after initiation of TB treatment in others.\n\n      Systematic empirical TB treatment (arm 2): In this arm:\n\n        -  TB screening point-of-care tests will not be used;\n\n        -  All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization;\n           ART (tenofovir-lamivudine/emtricitabine or zidovudine-lamivudine+ efavirenz)  will be\n           started 2 weeks after TB treatment initiation.\n\n      Both strategies will apply to the first 24 weeks in the trial (intervention period).\n\n      From week-24 to week-48, the choice of TB tests and the prescription of TB treatment will be\n      left upon the decision of the investigator in both trial arms.\n\n      Inclusion time: 24 months. Follow-up: each patient will be followed 48 weeks. Statistical\n      analysis: the primary analysis will be intention to treat. It will compare the 24-week\n      probability of death or invasive bacterial infection between arms.\n\n      Sample size: 1050 participants. This will allow demonstration of a 40% reduction in the\n      24-week probability of death or invasive bacterial infection in arm 2, compared to arm 1 (\u03b1\n      5%; 1-\u03b2 80%)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u226518 years;\n\n          -  HIV-1 infection as documented at any time prior to trial entry, as per national\n             testing procedures;\n\n          -  CD4 <100 cells/mm3;\n\n          -  No history of antiretroviral drug use (except transient ART for PMTCT);\n\n          -  Able to correctly understand the trial and to sign the informed consent.\n\n        Exclusion Criteria:\n\n          -  HIV-2 co-infection;\n\n          -  Contra-indication to efavirenz;\n\n          -  Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT)  >5 times the\n             upper limit of normal;\n\n          -  Creatinine clearance <50 ml/min;\n\n          -  Overt evidence that TB treatment should be started immediately;\n\n          -  History of TB treatment in the past 5 years;\n\n          -  Ongoing TB chemoprophylaxis (isoniazid preventive therapy);\n\n          -  Any condition that would lead to differ ART initiation (e.g. acute condition\n             requiring investigations and/or treatment prior to ART initiation);\n\n          -  Current pregnancy or breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1050", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057796", 
            "org_study_id": "ANRS 12290"
        }, 
        "intervention": [
            {
                "arm_group_label": "Xpert MTB/RIF\u00ae, Determine TB LAM, Chest X-ray", 
                "description": "The following point-of-care TB tests will be systematically performed:\nXpert MTB/RIF\u00ae  on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF\u00ae will also be performed on any relevant extra-pulmonary specimen.\nTB treatment will depend on the result of the tests:\nCriteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1).", 
                "intervention_name": "Xpert MTB/RIF\u00ae, Determine TB LAM, Chest X-ray", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": [
                    "Xpert MTB/RIF\u00ae, Determine TB LAM, Chest X-ray", 
                    "Rifampin, isoniazid, pyrazinamide, ethambutol"
                ], 
                "description": "ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.\nART will be initiated 2 weeks after the onset of TB treatment (V2)  for Arm 2", 
                "intervention_name": "ART (Atripla, Truvada, Efavirenz, Combivir)", 
                "intervention_type": "Drug", 
                "other_name": "ART"
            }, 
            {
                "arm_group_label": [
                    "Xpert MTB/RIF\u00ae, Determine TB LAM, Chest X-ray", 
                    "Rifampin, isoniazid, pyrazinamide, ethambutol"
                ], 
                "description": "Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: \u2022\tAll patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization", 
                "intervention_name": "Rifampin, isoniazid, pyrazinamide, ethambutol", 
                "intervention_type": "Drug", 
                "other_name": "Systematic Empiric treatment"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ethambutol", 
                "Isoniazid", 
                "Pyrazinamide", 
                "Rifampin", 
                "Efavirenz", 
                "Lamivudine, zidovudine drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV-1", 
            "Tuberculosis", 
            "Systematic empiric TB treatment", 
            "ART", 
            "TB diagnosis", 
            "Xpert MTB/RIF\u00ae", 
            "Urine LAM"
        ], 
        "lastchanged_date": "February 18, 2014", 
        "location": [
            {
                "contact": {
                    "email": "lborand@pasteur-kh.org", 
                    "last_name": "Laurence Borand, PharmD"
                }, 
                "facility": {
                    "address": {
                        "city": "Phnom Penh", 
                        "country": "Cambodia", 
                        "zip": "2318"
                    }, 
                    "name": "Sihanouk Hospital Center of Hope"
                }, 
                "investigator": {
                    "last_name": "Didier Laureillard, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "messou_eugene@yahoo.fr", 
                    "last_name": "Eugene Messou, MD PhD", 
                    "phone": "+225 21 75 59 60"
                }, 
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire", 
                        "state": "Yopougon", 
                        "zip": "1954"
                    }, 
                    "name": "CePReF Centre de Prise en charge de Recherche et de Formation"
                }, 
                "investigator": {
                    "last_name": "Christine Danel, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "conradmuzoora@yahoo.com", 
                    "last_name": "Conrad MUZOORA, MD", 
                    "phone": "+256 772 547 175"
                }, 
                "facility": {
                    "address": {
                        "city": "Mbarara", 
                        "country": "Uganda", 
                        "zip": "1956"
                    }, 
                    "name": "ISS ImmunoSuppression Service"
                }, 
                "investigator": {
                    "last_name": "Maryline Bonnet, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "didier.laureillard@yahoo.fr", 
                    "last_name": "Didier Laureillard, MD", 
                    "phone": "+84 169 7 061 034"
                }, 
                "facility": {
                    "address": {
                        "city": "Ho Chi Minh City", 
                        "country": "Vietnam"
                    }, 
                    "name": "Pham Ngoc Thach Hospital"
                }, 
                "investigator": {
                    "last_name": "Didier Laureillard, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Cambodia", 
                "C\u00f4te D'Ivoire", 
                "Uganda", 
                "Vietnam"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial", 
        "other_outcome": [
            {
                "measure": "Incidence of TB-associated IRIS", 
                "safety_issue": "No", 
                "time_frame": "24 Weeks and 48 Weeks"
            }, 
            {
                "measure": "Incidence of AIDS-defining diseases other than TB", 
                "safety_issue": "No", 
                "time_frame": "24 Weeks and 48 Weeks"
            }
        ], 
        "overall_contact": {
            "email": "xavier.blanc@chu-nantes.fr", 
            "last_name": "Fran\u00e7ois-Xavier Blanc, MD, PhD", 
            "phone": "+33 240 165 545"
        }, 
        "overall_contact_backup": {
            "email": "didier.laureillard@yahoo.fr", 
            "last_name": "Didier Laureillard, MD", 
            "phone": "+84 169 7 061 034"
        }, 
        "overall_official": [
            {
                "affiliation": "Universit\u00e9 de Nantes, Institut du thorax, CHU Nantes, France", 
                "last_name": "Fran\u00e7ois-Xavier Blanc, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Service de Pneumologie, CHU de Treichville, Abidjan, C\u00f4te d'Ivoire", 
                "last_name": "Kouao M\u00e9dard Serge Domoua, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Cambodia: Ministry of Health (National Ethics Committee for Health Research)", 
                "Cote d'Ivoire: National Research and Ethics Committee", 
                "Uganda: Ministry of Health", 
                "Vietnam: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is the composite of (i) 24-week all-cause mortality and (ii) 24-week incidence of invasive bacterial infections", 
            "measure": "All-cause mortality and incidence of invasive bacterial infections", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057796"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of confirmed/probable/possible TB", 
                "safety_issue": "No", 
                "time_frame": "24 Weeks and 48 weeks"
            }, 
            {
                "measure": "Incidence of grade 3 or 4 adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "24 Weeks and 48 weeks"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}